Overview

A Study to Evaluate Nutropin AQ for the Treatment of Growth Restriction in Children With Cystic Fibrosis

Status:
Completed
Trial end date:
2007-05-01
Target enrollment:
Participant gender:
Summary
This is a Phase II, multicenter, randomized, controlled, open-label trial of the safety and efficacy of Nutropin AQ administered subcutaneously (SC) daily in prepubertal children with CF and growth restriction.
Phase:
Phase 2
Details
Lead Sponsor:
Genentech, Inc.